Search Results

Your search matched 7 results


The U.S. | Blog

Democrats have revealed that the next major legislative package—colloquially known as the infrastructure package—will likely include provisions to lower prescription drug prices.


Biden Supports Waiving IP Protections for COVID-19 Vaccines. | Blog

As you may have read, the Biden administration announced last week that it will support a proposal to temporarily waive certain intellectual property (IP) protections for COVID-19 vaccines and therapies.


Biden Executive Order Makes Communicating Your Value Proposition More Important than Ever | Blog

This month, we’ve seen a flurry of activity that confirms Washington will be focused on drug pricing this summer, and it’s coming from all directions: Congress, the Biden Administration, and Courts.


Multiple inflection points are colliding that will force action on drug pricing in the U.S. | Blog

An update on the latest developments in Washington critical to Pharma leaders.


Post–Biogen’s Aduhelm Approval, Prepare for Increased Scrutiny | Blog

Within a few days of the Aduhelm approval, the conversation quickly shifted from the first treatment for Alzheimer’s disease to the exorbitant cost ($56,000 annually) and whether the budgetary impact on society of the drug’s broad label is worth the therapeutic outcomes.


What Biogen’s Alzheimer’s Drug Approval Means for Life Sciences Companies | Blog

In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.


A New Drug Price Deal Signals Significant Policy Shift | Blog

This month policies aimed at lowering drug prices are back on the table.